NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected, ART-treated HIV patients

European Journal of Immunology

Volumn 42, Issue 11, 2012, Pages 3038-3048

  Harari, Alexandre ^a,b   Rozot, Virginie ^a   Cavassini, Matthias ^a   Enders, Felicitas Bellutti ^a   Vigano, Selena ^a   Tapia, Gonzalo ^a   Castro, Erika ^a   Burnet, Séverine ^a   Lange, Joep ^c   Moog, Christiane ^d   Garin, Daniel ^e   Costagliola, Dominique ^f   Autran, Brigitte ^f   Pantaleo, Giuseppe ^a,b   Bart, Pierre Alexandre ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Swiss Vaccine Research Institute   (Switzerland)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d UNIVERSITÉ DE STRASBOURG   (France)

^e IRBA   (France)

^f SORBONNE UNIVERSITÉ   (France)

Author keywords

HIV; Immunogenicity; Poxvirus; Therapeutic vaccine

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CREATINE KINASE; GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEF PROTEIN; NYVAC B VACCINE; POL PROTEIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CLADISTICS; CLINICAL ARTICLE; CORRELATION ANALYSIS; CREATINE KINASE BLOOD LEVEL; CYTOKINE RELEASE; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; FATIGUE; FLOW CYTOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE PAIN; LYMPHOCYTE PROLIFERATION; MALE; MALE HOMOSEXUAL; PATIENT MONITORING; POXVIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SIDE EFFECT; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL GROWTH PROCESSES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HIV; HIV INFECTIONS; HUMANS; INTERFERON-GAMMA; MALE; MIDDLE AGED; RNA, VIRAL; SWITZERLAND; VIRAL VACCINES;

EID: 84868130504     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201242696     Document Type: Article

References (49)

1. Chun, T. W., Justement, J. S., Murray, D., Hallahan, C. W., Maenza, J., Collier, A. C., Sheth, P. M. et al., Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS 2010. 24: 2803-2808.
2. Palella, F. J., Jr., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J. et al., Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. New Engl. J. Med. 1998. 338: 853-860.
3. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008. 372: 293-299.
4. Lewden, C., Chene, G., Morlat, P., Raffi, F., Dupon, M., Dellamonica, P., Pellegrin, J. L. et al., HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J. Acquir. Immune Defic. Syndr. 2007. 46: 72-77.
5. Davey, R. T., Jr., Bhat, N., Yoder, C., Chun, T. W., Metcalf, J. A., Dewar, R., Natarajan, V. et al., HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl. Acad. Sci. USA 1999. 96: 15109-15114.
6. Oxenius, A., Price, D. A., Gunthard, H. F., Dawson, S. J., Fagard, C., Perrin, L., Fischer, M. et al., Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc. Natl. Acad. Sci. USA 2002. 99: 13747-13752.
7. Ortiz, G. M., Wellons, M., Brancato, J., Vo, H. T., Zinn, R. L., Clarkson, D. E., Van Loon, K. et al., Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc. Natl. Acad. Sci. USA 2001. 98: 13288-13293.
8. Autran, B. and Carcelain, G., AIDS. Boosting immunity to HIV-can the virus help? Science 2000. 290: 946-949.
9. Wang, H. B., Kondo, A., Yoshida, A., Yoshizaki, S., Abe, S., Bao, L. L., Mizuki, N. et al., Partial protection against SIV challenge by vaccination of adenovirus and MVA vectors in rhesus monkeys. Gene Ther. 2010. 17: 4-13.
10. Hel, Z., Venzon, D., Poudyal, M., Tsai, W. P., Giuliani, L., Woodward, R., Chougnet, C. et al., Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nat. Med. 2000. 6: 1140-1146.
11. Angel, J. B., Routy, J. P., Tremblay, C., Ayers, D., Woods, R., Singer, J., Bernard, N. et al., A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune. AIDS 2011. 25: 731-739.
12. Autran, B., Carcelain, G., Combadiere, B. and Debre, P., Therapeutic vaccines for chronic infections. Science 2004. 305: 205-208.
13. Levy, Y., Durier, C., Lascaux, A. S., Meiffredy, V., Gahery-Segard, H., Goujard, C., Rouzioux, C. et al., Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals. AIDS 2006. 20: 405-413.
14. Schooley, R. T., Spino, C., Kuritzkes, D., Walker, B. D., Valentine, F. A., Hirsch, M. S., Cooney, E. et al., Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS clinical trials groups 209 and 214. J. Infect. Dis. 2000. 182: 1357-1364.
15. Kran, A. M., Sommerfelt, M. A., Sorensen, B., Nyhus, J., Baksaas, I., Bruun, J. N. and Kvale, D., Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization. Vaccine 2005. 23: 4011-4015.
16. Kinloch-de Loes, S., Hoen, B., Smith, D. E., Autran, B., Lampe, F. C., Phillips, A. N., Goh, L. E. et al., Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J. Infect. Dis. 2005. 192: 607-617.
17. Fernandez-Cruz, E., Moreno, S., Navarro, J., Clotet, B., Bouza, E., Carbone, J., Pena, J. M. et al., Therapeutic immunization with an inactivated HIV-1 immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects. Vaccine 2004. 22: 2966-2973.
18. Goujard, C., Marcellin, F., Hendel-Chavez, H., Burgard, M., Meiffredy, V., Venet, A., Rouzioux, C. et al., Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 randomized study. AIDS Res. Hum. Retroviruses 2007. 23: 1105-1113.
19. Levy, Y., Gahery-Segard, H., Durier, C., Lascaux, A. S., Goujard, C., Meiffredy, V., Rouzioux, C. et al., Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. AIDS 2005. 19: 279-286.
20. Casazza, J., Bowman, K., Ambrozak, D., Gordon, I., Roederer, M., Enama, M., Nason, M. et al., Increased HIV-specific immunity in HIV-infected individuals vaccinated with a DNA prime, rAd5 boost regimen CROI 2010.
21. Li, J. Z., Brumme, Z. L., Brumme, C. J., Wang, H., Spritzler, J., Robertson, M. N., Lederman, M. M. et al., Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial. J. Infect. Dis. 2011. 203: 976-983.
22. Autran, B., Murphy, R. L., Costagliola, D., Tubiana, R., Clotet, B., Gatell, J., Staszewski, S. et al., Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). AIDS 2008. 22: 1313-1322.
23. Papagno, L., Alter, G., Assoumou, L., Murphy, R. L., Garcia, F., Clotet, B., Larsen, M. et al., Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine. AIDS 2011. 25: 27-36.
24. Zimmerli, S. C., Harari, A., Cellerai, C., Vallelian, F., Bart, P. A. and Pantaleo, G., HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc. Natl. Acad. Sci. USA 2005. 102: 7239-7244.
25. Betts, M. R., Nason, M. C., West, S. M., De Rosa, S. C., Migueles, S. A., Abraham, J., Lederman, M. M. et al., HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006. 107: 4781-4789.
26. Seder, R. A., Darrah, P. A. and Roederer, M., T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 2008. 8: 247-258.
27. Kiepiela, P., Ngumbela, K., Thobakgale, C., Ramduth, D., Honeyborne, I., Moodley, E., Reddy, S. et al., CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 2007. 13: 46-53.
28. Puissant-Lubrano, B., Combadiere, B., Duffy, D., Wincker, N., Frachette, M. J., Ait-Mohand, H., Verrier, B. et al., Influence of antigen exposure on the loss of long-term memory to childhood vaccines in HIV-infected patients. Vaccine 2009. 27: 3576-3583.
29. Harari, A., Enders, F. B., Cellerai, C., Bart, P. A. and Pantaleo, G., Distinct profiles of cytotoxic granules in memory CD8 T cells correlate with function, differentiation stage, and antigen exposure. Journal Virol. 2009. 83: 2862-2871.
30. Bart, P. A., Harari, A. and Pantaleo, G., Clinical studies of experimental vaccines. Curr. Opin. HIV AIDS 2006. 1: 286-293.
31. Betts, M. R. and Harari, A., Phenotype and function of protective T cell immune responses in HIV. Curr. Opin. HIV AIDS 2008. 3: 349-355.
32. Migueles, S. A., Laborico, A. C., Shupert, W. L., Sabbaghian, M. S., Rabin, R., Hallahan, C. W., Van Baarle, D. et al., HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat. Immun. 2002. 3: 1061-1068.
33. Iyasere, C., Tilton, J. C., Johnson, A. J., Younes, S., Yassine-Diab, B., Sekaly, R. P., Kwok, W. W. et al., Diminished proliferation of human immunodeficiency virus-specific CD4+ T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2. J. Virol. 2003. 77: 10900-10909.
34. Younes, S. A., Yassine-Diab, B., Dumont, A. R., Boulassel, M. R., Grossman, Z., Routy, J. P. and Sekaly, R. P., HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J. Exp. Med. 2003. 198: 1909-1922.
35. Spentzou, A., Bergin, P., Gill, D., Cheeseman, H., Ashraf, A., Kaltsidis, H., Cashin-Cox, M. et al., Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates. J. Infect. Dis. 2010. 201: 720-729.
36. Yang, H., Wu, H., Hancock, G., Clutton, G., Sande, N., Xu, X., Yan, H. et al., Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection. J Infect Dis 2012.
37. Freel, S. A., Picking, R. A., Ferrari, G., Ding, H., Ochsenbauer, C., Kappes, J. C., Kirchherr, J. L. et al., Initial HIV-1 antigen-specific CD8 +T cells in acute HIV-1 infection inhibit transmitted/founder virus replication. J. Virol. 2012. 86: 6835-6846.
38. Freel, S. A., Lamoreaux, L., Chattopadhyay, P. K., Saunders, K., Zarkowsky, D., Overman, R. G., Ochsenbauer, C. et al., Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination. J. Virol. 2010. 84: 4998-5006.
39. Persaud, D., Luzuriaga, K., Ziemniak, C., Muresan, P., Greenough, T., Fenton, T., Blackford, A. et al., Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4+ T-cell latent HIV reservoir. AIDS 2011. 25: 2227-2234.
40. El-Sadr, W. M., Lundgren, J. D., Neaton, J. D., Gordin, F., Abrams, D., Arduino, R. C., Babiker, A. et al., CD4+ count-guided interruption of antiretroviral treatment. New Engl. J. Med. 2006. 355: 2283-2296.
41. Skiest, D. J., Krambrink, A., Su, Z., Robertson, K. R. and Margolis, D. M., Improved measures of quality of life, lipid profile, and lipoatrophy after treatment interruption in HIV-infected patients with immune preservation: results of ACTG 5170. J. Acquir. Immune Defic. Syndr. 2008. 49: 377-383.
42. Combadiere, B., Boissonnas, A., Carcelain, G., Lefranc, E., Samri, A., Bricaire, F., Debre, P. et al., Distinct time effects of vaccination on long-term proliferative and IFN-gamma-producing T cell memory to smallpox in humans. J. Exp. Med. 2004. 199: 1585-1593.
43. Leparc-Goffart, I., Poirier, B., Garin, D., Tissier, M. H., Fuchs, F. and Crance, J. M., Standardization of a neutralizing anti-vaccinia antibodies titration method: an essential step for titration of vaccinia immunoglobulins and smallpox vaccines evaluation. J. Clin. Virol. 2005. 32: 47-52.
44. Gomez, C. E., Najera, J. L., Jimenez, E. P., Jimenez, V., Wagner, R., Graf, M., Frachette, M. J. et al., Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. Vaccine 2007. 25: 2863-2885.
45. Frahm, N. and Brander, C., Optimal CTL epitope identification in HIV clade B and non-clade B infection. HIV Mol. Immunol. 2005: 3-20.
46. Currier, J. R., Kuta, E. G., Turk, E., Earhart, L. B., Loomis-Price, L., Janetzki, S., Ferrari, G. et al., A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J. Immunol. Methods 2002. 260: 157-172.
47. Harari, A., Bart, P. A., Stohr, W., Tapia, G., Garcia, M., Medjitna-Rais, E., Burnet, S. et al., An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J. Exp. Med. 2008. 205: 63-77.
48. Cellerai, C., Perreau, M., Rozot, V., Enders, F. B., Pantaleo, G. and Harari, A., Proliferation capacity and cytotoxic activity are mediated by functionally and phenotypically distinct virus-specific CD8 T cells defined by interleukin-7R{alpha} (CD127) and perforin expression. J. Virol. 2010. 84: 3868-3878.
49. Roederer, M., Nozzi, J. L. and Nason, M. C., SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 2011. 79A: 167-174.